Predicting Vibrio cholerae infection and symptomatic disease: a systems serology study.


Journal

The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019

Informations de publication

Date de publication:
04 2023
Historique:
received: 10 08 2022
revised: 18 11 2022
accepted: 09 12 2022
medline: 4 4 2023
pubmed: 13 3 2023
entrez: 12 3 2023
Statut: ppublish

Résumé

Vibriocidal antibodies are currently the best characterised correlate of protection against cholera and are used to gauge immunogenicity in vaccine trials. Although other circulating antibody responses have been associated with a decreased risk of infection, the correlates of protection against cholera have not been comprehensively compared. We aimed to analyse antibody-mediated correlates of protection from both V cholerae infection and cholera-related diarrhoea. We conducted a systems serology study that analysed 58 serum antibody biomarkers as correlates of protection against V cholerae O1 infection or diarrhoea. We used serum samples from two cohorts: household contacts of people with confirmed cholera in Dhaka, Bangladesh, and cholera-naive volunteers who were recruited at three centres in the USA, vaccinated with a single dose of CVD 103-HgR live oral cholera vaccine, and then challenged with V cholerae O1 El Tor Inaba strain N16961. We measured antigen-specific immunoglobulin responses against antigens using a customised Luminex assay and used conditional random forest models to examine which baseline biomarkers were most important for classifying individuals who went on to develop infection versus those who remained uninfected or asymptomatic. V cholerae infection was defined as having a positive stool culture result on days 2-7 or day 30 after enrolment of the household's index cholera case and, in the vaccine challenge cohort, was the development of symptomatic diarrhoea (defined as two or more loose stools of ≥200 mL each, or a single loose stool of ≥300 mL over a 48-h period). In the household contact cohort (261 participants from 180 households), 20 (34%) of the 58 studied biomarkers were associated with protection against V cholerae infection. We identified serum antibody-dependent complement deposition targeting the O1 antigen as the most predictive correlate of protection from infection in the household contacts, whereas vibriocidal antibody titres ranked lower. A five-biomarker model predicted protection from V cholerae infection with a cross-validated area under the curve (cvAUC) of 79% (95% CI 73-85). This model also predicted protection against diarrhoea in unvaccinated volunteers challenged with V cholerae O1 after vaccination (n=67; area under the curve [AUC] 77%, 95% CI 64-90). Although a different five-biomarker model best predicted protection from the development of cholera diarrhoea in the challenged vaccinees (cvAUC 78%, 95% CI 66-91), this model did poorly at predicting protection against infection in the household contacts (AUC 60%, 52-67). Several biomarkers predict protection better than vibriocidal titres. A model based on protection against infection among household contacts was predictive of protection against both infection and diarrhoeal illness in challenged vaccinees, suggesting that models based on observed conditions in a cholera-endemic population might be more likely to identify broadly applicable correlates of protection than models trained on single experimental settings. National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development, National Institutes of Health.

Sections du résumé

BACKGROUND
Vibriocidal antibodies are currently the best characterised correlate of protection against cholera and are used to gauge immunogenicity in vaccine trials. Although other circulating antibody responses have been associated with a decreased risk of infection, the correlates of protection against cholera have not been comprehensively compared. We aimed to analyse antibody-mediated correlates of protection from both V cholerae infection and cholera-related diarrhoea.
METHODS
We conducted a systems serology study that analysed 58 serum antibody biomarkers as correlates of protection against V cholerae O1 infection or diarrhoea. We used serum samples from two cohorts: household contacts of people with confirmed cholera in Dhaka, Bangladesh, and cholera-naive volunteers who were recruited at three centres in the USA, vaccinated with a single dose of CVD 103-HgR live oral cholera vaccine, and then challenged with V cholerae O1 El Tor Inaba strain N16961. We measured antigen-specific immunoglobulin responses against antigens using a customised Luminex assay and used conditional random forest models to examine which baseline biomarkers were most important for classifying individuals who went on to develop infection versus those who remained uninfected or asymptomatic. V cholerae infection was defined as having a positive stool culture result on days 2-7 or day 30 after enrolment of the household's index cholera case and, in the vaccine challenge cohort, was the development of symptomatic diarrhoea (defined as two or more loose stools of ≥200 mL each, or a single loose stool of ≥300 mL over a 48-h period).
FINDINGS
In the household contact cohort (261 participants from 180 households), 20 (34%) of the 58 studied biomarkers were associated with protection against V cholerae infection. We identified serum antibody-dependent complement deposition targeting the O1 antigen as the most predictive correlate of protection from infection in the household contacts, whereas vibriocidal antibody titres ranked lower. A five-biomarker model predicted protection from V cholerae infection with a cross-validated area under the curve (cvAUC) of 79% (95% CI 73-85). This model also predicted protection against diarrhoea in unvaccinated volunteers challenged with V cholerae O1 after vaccination (n=67; area under the curve [AUC] 77%, 95% CI 64-90). Although a different five-biomarker model best predicted protection from the development of cholera diarrhoea in the challenged vaccinees (cvAUC 78%, 95% CI 66-91), this model did poorly at predicting protection against infection in the household contacts (AUC 60%, 52-67).
INTERPRETATION
Several biomarkers predict protection better than vibriocidal titres. A model based on protection against infection among household contacts was predictive of protection against both infection and diarrhoeal illness in challenged vaccinees, suggesting that models based on observed conditions in a cholera-endemic population might be more likely to identify broadly applicable correlates of protection than models trained on single experimental settings.
FUNDING
National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development, National Institutes of Health.

Identifiants

pubmed: 36907197
pii: S2666-5247(22)00391-3
doi: 10.1016/S2666-5247(22)00391-3
pmc: PMC10186354
mid: NIHMS1887321
pii:
doi:

Substances chimiques

Antibodies, Bacterial 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e228-e235

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI130378
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI135115
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD102540
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137164
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI106878
Pays : United States

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Open Forum Infect Dis. 2019 Feb 11;6(4):ofz057
pubmed: 30997364
PLoS Negl Trop Dis. 2008 Apr 09;2(4):e221
pubmed: 18398491
J Infect Dis. 2018 Jul 13;218(4):645-653
pubmed: 29659916
BMC Bioinformatics. 2020 Jul 14;21(1):307
pubmed: 32664864
Immunology. 2018 Mar;153(3):279-289
pubmed: 29139548
Clin Vaccine Immunol. 2017 Jan 5;24(1):
pubmed: 27847368
Clin Infect Dis. 2016 Jun 1;62(11):1329-1335
pubmed: 27001804
Clin Infect Dis. 2009 Nov 15;49(10):1473-9
pubmed: 19842974
Retrovirology. 2017 Dec 21;14(1):57
pubmed: 29268769
J Infect Dis. 2021 Feb 3;223(2):342-351
pubmed: 32610345
mBio. 2016 Dec 20;7(6):
pubmed: 27999163
J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S732-S737
pubmed: 34668561
Sci Transl Med. 2013 Jul 3;5(192):192ra86
pubmed: 23825302
Sci Transl Med. 2019 Feb 20;11(480):
pubmed: 30787170
Vaccine. 2018 May 11;36(20):2768-2773
pubmed: 29655627
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33180929
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1223-1227
pubmed: 31718760
Nat Med. 2021 Mar;27(3):454-462
pubmed: 33589825
BMC Bioinformatics. 2008 Jul 11;9:307
pubmed: 18620558
mBio. 2022 Oct 26;13(6):e0190022
pubmed: 36286520
Cell. 2016 Oct 6;167(2):433-443.e14
pubmed: 27667685
BMC Bioinformatics. 2007 Jan 25;8:25
pubmed: 17254353
PLoS One. 2018 Jan 2;13(1):e0190026
pubmed: 29293563
PLoS Negl Trop Dis. 2015 Jul 08;9(7):e0003881
pubmed: 26154421
mSphere. 2021 Apr 28;6(2):
pubmed: 33910997
Clin Vaccine Immunol. 2012 Jun;19(6):842-8
pubmed: 22518009
mSphere. 2019 Nov 27;4(6):
pubmed: 31776240

Auteurs

Kirsten E Wiens (KE)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology and Biostatistics, Temple University College of Public Health, Philadelphia, PA, USA.

Anita S Iyer (AS)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Taufiqur R Bhuiyan (TR)

Infectious Diseases Division, International Centre for Diarrheoal Disease Research, Bangladesh, Dhaka, Bangladesh.

Lenette L Lu (LL)

Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine and Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Parkland Health and Hospital System, Dallas, TX, USA.

Deniz Cizmeci (D)

Ragon Institute of MGH, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA.

Matthew J Gorman (MJ)

Ragon Institute of MGH, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA.

Dansu Yuan (D)

Ragon Institute of MGH, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA.

Rachel L Becker (RL)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.

Edward T Ryan (ET)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.

Stephen B Calderwood (SB)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Regina C LaRocque (RC)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Fahima Chowdhury (F)

Infectious Diseases Division, International Centre for Diarrheoal Disease Research, Bangladesh, Dhaka, Bangladesh.

Ashraful I Khan (AI)

Infectious Diseases Division, International Centre for Diarrheoal Disease Research, Bangladesh, Dhaka, Bangladesh.

Myron M Levine (MM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

Wilbur H Chen (WH)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

Richelle C Charles (RC)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.

Andrew S Azman (AS)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Firdausi Qadri (F)

Infectious Diseases Division, International Centre for Diarrheoal Disease Research, Bangladesh, Dhaka, Bangladesh.

Galit Alter (G)

Department of Medicine, Harvard Medical School, Boston, MA, USA; Ragon Institute of MGH, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA.

Jason B Harris (JB)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: jbharris@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH